Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients

Won Young Tak, Masatoshi Kudo, Ho Yeong Lim et al.|Investigational New Drugs|2018

Cited by 49